HomeCompareAMGN vs RTX

AMGN vs RTX: Dividend Comparison 2026

AMGN yields 2.77% · RTX yields 1.45%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $130.3K in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
RTX
RTX
● Live price
1.45%
Share price
$187.15
Annual div
$2.72
5Y div CAGR
32.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.8K
Annual income
$3,684.67
Full RTX calculator →

Portfolio growth — AMGN vs RTX

📍 AMGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNRTX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + RTX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
RTX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
RTX
Annual income on $10K today (after 15% tax)
$123.54/yr
After 10yr DRIP, annual income (after tax)
$3,131.97/yr
At 15% tax rate, AMGN beats the other by $56,150.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + RTX for your $10,000?

AMGN: 50%RTX: 50%
100% RTX50/50100% AMGN
Portfolio after 10yr
$99.0K
Annual income
$36,714.27/yr
Blended yield
37.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMGN right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
RTX
Analyst Ratings
17
Buy
9
Hold
Consensus: Buy
Price Target
$219.20
+17.1% upside vs current
Range: $168.00 — $240.00
Altman Z
2.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
RTX buys
0
No recent congressional trades found for AMGN or RTX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNRTX
Forward yield2.77%1.45%
Annual dividend / share$9.66$2.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%32.4%
Portfolio after 10y$164.2K$33.8K
Annual income after 10y$69,743.86$3,684.67
Total dividends collected$133.8K$12.1K
Payment frequencyquarterlyquarterly
SectorHealthcareIndustrials
Analyst consensusBuyBuy
Analyst price target$347.73$219.20

Year-by-year: AMGN vs RTX ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrRTX PortfolioRTX Income/yrGap
1← crossover$11,111$411.31$10,892$192.43+$219.00AMGN
2$12,524$634.70$11,914$259.36+$610.00AMGN
3$14,394$993.52$13,099$351.03+$1.3KAMGN
4$16,987$1,585.83$14,494$477.56+$2.5KAMGN
5$20,776$2,599.19$16,162$653.83+$4.6KAMGN
6$26,645$4,414.70$18,196$902.17+$8.4KAMGN
7$36,373$7,863.06$20,726$1,256.79+$15.6KAMGN
8$53,826$14,907.12$23,948$1,771.40+$29.9KAMGN
9$88,231$30,636.84$28,157$2,532.66+$60.1KAMGN
10$164,151$69,743.86$33,813$3,684.67+$130.3KAMGN

AMGN vs RTX: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

RTXIndustrials

RTX Corporation, an aerospace and defense company, provides systems and services for the commercial, military, and government customers in the United States and internationally. It operates through three segments: Collins Aerospace, Pratt & Whitney, and Raytheon. The Collins Aerospace Systems segment offers aerospace and defense products, and aftermarket service solutions for civil and military aircraft manufacturers and commercial airlines, as well as regional, business, and general aviation, defense, and commercial space operations. This segment also designs, produces, and supports cabin interior, including oxygen systems, food and beverage preparation, storage and galley systems, and lavatory and wastewater management systems; battlespace, test and training range systems, crew escape systems, and simulation and training solutions; information management services; and aftermarket services that include spare parts, overhaul and repair, engineering and technical support, training and fleet management solutions, and asset and information management services. Its Pratt & Whitney segment supplies aircraft engines for commercial, military, business jet, and general aviation customers; and produces, sells, and services military and commercial auxiliary power units. The Raytheon segment provides defensive and offensive threat detection, tracking, and mitigation capabilities for U.S., foreign government, and commercial customers. The company was formerly known as Raytheon Technologies Corporation and changed its name to RTX Corporation in July 2023. RTX Corporation was incorporated in 1934 and is headquartered in Arlington, Virginia.

Full RTX Calculator →
📬

Get this AMGN vs RTX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.